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A B S T R A C T
Mammary serine protease inhibitor or Maspin has been characterized as a class II tumor suppressor gene in
several cancer types, among them prostate cancer (CaP). Androgen ablation is an effective therapy for CaP, but
with short-term effectiveness, thus new therapeutic strategies are actively sought. The present study is aimed to
explore the effects of a glucosamine derivative, 2-(N-Carbobenzyloxy)L-phenylalanylamido-2-deoxy-β-D-glucose
(NCPA), on two CaP cell lines, PC3 and LNCaP.
In particular we analyzed the impact of NCPA on Maspin production, cell viability and cell cycle progression
and apoptosis/necrosis pathway activation in PC3 and LNCaP cell lines.
NCPA is able to stimulate Maspin production in PC3 and not in LNCaP cell lines. NCPA blocks the PC3 cell
cycle in G1 phase, by inhibiting Cyclin D1 production and induces the apoptosis, therefore interfering with
aggressiveness of this androgen-insensitive cell line. Moreover, NCPA is able to induce the expression of Maspin
in LNCaP cell line treated with androgen receptor inhibitor, Bicalutamide, and in turn to stimulate the apoptosis
of these cells.
These findings suggest that NCPA, stimulating the endogenous production of a tumor suppressor protein,
could be useful in the design of new therapeutic strategies for treatment of CaP.
1. Introduction
Prostate Cancer (CaP) is the most common form of male tumor and
is the second leading cause of cancer death. The disease progresses from
intra-epithelial neoplasia to locally invasive adenocarcinoma, and then
to hormone-refractory metastatic carcinoma [1]. Androgen ablation has
proved to be an effective therapy for metastatic prostate cancer, but the
regression of metastatic lesions lasts only 18–24 months [2]. The ma-
jority of men becomes refractory to androgen blockade, with a median
survival time of 9–12 months. In addition to androgen receptor (AR)
signaling, it has become evident that other signaling pathways are in-
volved in prostate cancer development and progression [3].
Oncogenic processes, such as mutation of Ras and activation of Bcl2,
or loss of function by tumor suppressor genes also contribute to tumor
progression. Maspin (Mammary Serine Protease Inhibitor or SerpinB5)
is a tumor-suppressing serine protease inhibitor initially isolated from
normal human mammary epithelial cells. Maspin is a 42 kDa protein
and is an unusual member of Serpin superfamily, which includes in-
hibitory members that target proteases, as well as non-inhibitory
members that possess a diverse array of functions [4].
Functional studies have demonstrated that Maspin inhibits tumor
invasion and motility of human mammary tumor cells in cell culture
models [5], as well as tumor growth and metastasis in the nude mice
assay [6]. The overexpression of Maspin is a predicting favorable
prognosis factor in breast cancer and in lung squamous cell carcinoma
[7,8]. However, the exact role of Maspin in tumors is still controversial
since conflicting experimental and clinical results are reported. Al-
though the significance of Maspin expression varies in different tumors,
the expression of Maspin is frequently absent in prostate cancer [9]. In
the prostate, expression of Maspin is regulated by both positive and
negative mechanisms at the transcriptional level. It has been identified
the Ets site as a positive regulator of Maspin expression, and the hor-
mone responsive element (HRE) sites that bind the androgen receptor
as cis elements involved in negatively regulated Maspin transcription
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[10].
In the androgen-sensitive LNCaP cells, androgen receptor can re-
cognize and bind to the androgen responsive element (ARE), and then
inhibits the activity of Maspin promoter. Androgen down-regulates
Maspin expression and the androgen ablation induces Maspin gene
expression in LNCaP cells [11]. Maspin expression that correlates with
good prognosis, may serve as a biomarker for prostate cancer cells re-
sponding to androgenic ablation therapy [11]. The repressive function
of ARE of the Maspin promoter is inactive in androgen-insensitive PC3
cells; in these cells, the protein RelB could be a modulator that bypasses
the normal expression control of Maspin production [9]. Moreover, the
repression of translocation into the nucleus of IKKα, a crucial upstream
molecule in both classical and alternative NF-κB signaling pathway
[12,13], has been associated with repression of the metastatic pheno-
type. Luo et al. [14] demonstrated that the nuclear localized IKKα in-
teracts with the Maspin promoter and causes transient repression of
Maspin expression in prostate cancer.
In the last years, in our laboratory, we studied the effects on in-
flammatory pathways of some peptidyl-derivatives of glucosamine
[15], a natural aminosugar present in extracellular matrix glycosami-
noglycans. We found that some of these glucosamine derivatives, i.e. 2-
(N-Acetyl)-L-phenylalanylamido-2-deoxy-β-D-glucose (NAPA) and 2-(N-
Carbobenzyloxy)L-phenylalanylamido-2-deoxy-β-D-glucose (NCPA),
were able to inhibit the migration into the nucleus of IKKα and NAPA
was also able to partially inhibit IKKα kinase activity [16]. Taking into
account the role of nuclear IKKα in cancer progression through
repression of Maspin expression, we investigated whether these mole-
cules were able to stimulate the Maspin expression by inhibiting IKKα
nuclear migration in 143B osteosarcoma cells, demonstrating that
NCPA was strongly able to interfere with this event [17]. Considering
the role of Maspin in prostate cancer, we decided to test whether NCPA
was able to stimulate the production of Maspin in two different prostate
carcinoma cell lines, androgen-insensitive PC3 and androgen-sensitive
LNCaP.
2. Material and methods
2.1. Cell culture
Human prostate carcinoma cell lines PC3 and LNCaP, obtained from
the American Type Culture Collection (ATCC, Rockville, MD, USA),
were used. Cells were cultured in RPMI 1640 (Sigma Aldrich, St. Louis,
MO, USA) supplemented with 10% fetal bovine serum (FBS), L-gluta-
mine, 1% sodium pyruvate, 100 U/mL of penicillin (final concentra-
tion), and 100 μg/mL of streptomycin (final concentration) (penicillin/
streptomycin, Sigma Aldrich). Both cell lines were cultured at 37 °C and
5% CO2 according to ATCC recommendations. Experiments were per-
formed using 80% confluent monolayer cells.
2.2. Cell treatment
Cells were left untreated (CTL) or treated with 0.5mM 2-(N-
Fig. 1. Effect of NCPA on cell viability. A: Cell viability was assessed by MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-
tetrazolium) based colorimetric assay. Cells were left untreated (CTL) or treated with 0.1, 0.5 and 1mM NCPA, for 24 h, 48 h and 72 h; B: Representative image of
cells untreated (CTL) or treated with 0.5 mM NCPA for 24 h, 48 h and 72 h. Experiments were repeated at least three times. Photographs were taken with Leica DM IL
LED using AF6000 modular Miscroscope (original magnification 20x).
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Carbobenzyloxy)-L- phenylalanylamido-2-deoxy-β-D-glucose (NCPA),
molecule synthesized in our laboratory [15], for the required time. To
inhibit the androgen receptor, cells were pretreated ON with 120 μM
Bicalutamide (Sigma Aldrich) and then treated with 0.5 mM NCPA plus
40 μM Bicalutamide, for the required time.
Experiments were independently repeated at least three times.
2.3. Cell viability
To detect potential cytotoxic effects of NCPA at concentrations and
times used, the survival of the cells treated with this molecule was
evaluated using MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carbox-
ymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium) based colori-
metric assay (Promega Corporation, Madison, WI, USA), according to
the manufacturer's instructions. Briefly, 1× 103 PC3 cells and 3×103
LNCaP cells per well, according to growth rate, were seeded in a 96-
well plate. MTS was added to the well containing untreated and treated
cells, 24 h, 48 h and 72 h after treatment. Spectrophotometric absor-
bance was measured at 492 nm.
Cells were observed at 24 h, 48 h and 72 h under optical microscope,
by Leica DM IL LED using AF6000 modular Microscope.
2.4. RNA extraction and reverse-transcription
Total RNA was extracted with TRIZOL (Invitrogen, Thermo Fisher
Scientific), purified using micro RNeasy column (Qiagen, Valencia, CA,
USA) and reverse transcribed by TetroReverse transcriptase enzyme,
(Bioline, London, UK), according to the manufacturers’ instructions.
2.5. Quantitative-Real Time-PCR
Quantitative-Real Time-PCR analysis was performed using an ABI
Prism 7300 (Applied Biosystems, Thermo Fisher Scientific).
Amplification was carried out using SensimixPlus SYBR Master mix
(Bioline). Primers were designed using Primer Express software
(Applied Biosystems) and were synthesized by Biofab Research (Rome,
Italy), Maspin (NM_002639) forward: 5′-GCCAGGAGCACGGATCCT-3′
and reverse: 5′-GTTGTGCCTGATGATGTAAATAAAGG-3′, GAPDH
(NM_002046) forward: 5′-GGAGTCAACGGATTTGGTCGTA-3′ and re-
verse: 5′-GGCAACAATATCCACTTTACCAGAGT-3’.
Relative expression levels were normalized with glyceraldheyde-3-
phosphate dehydrogenase (GAPDH) as housekeeping gene. Data were
analyzed by 2−ΔΔCt method [18] and expressed as fold change com-
pared to CTL.
2.6. Western blotting
To analyze the effect of NCPA on Maspin protein expression, we
performed western blot experiments. Cells, untreated and treated as
above described, were washed with phosphate buffer saline (PBS) and
lysated by nuclear extract kit (Active Motif, Carlsbad, CA, USA) to se-
parate the cytosolic from nuclear extract in accordance with manufac-
turer's instructions. Extracts were resolved on Mini-protean TGX precast
gels (Bio-Rad Laboratories, Hercules, CA, USA) and transferred to PVDF
membranes (Bio-Rad) and probed with specific antibody, in accordance
with the manufacturer's instructions. Antibody anti-Maspin was from
BD Pharmingen (BD Biosciences, San Jose, CA, USA).
2.7. Immunocytochemistry
Immunostaining was performed by an automated staining system
(Ventana BenchMark ULTRA, Roche diagnostic, Monza-Italy) in ac-
cordance with the manufacturer's instructions. Antigen epitopes were
retrieved using Ventana Benchmark CC1 standard program. The
Fig. 2. NCPA enhances Maspin production in PC3 cells. A:
Proteins from PC3 cells, untreated (CTL) or treated with
0.5 mM NCPA for 24 h, 48 h and 72 h, were extracted and
nuclear extract was analyzed by Western blot, using anti-
Maspin antibody and anti-Fibrillarin as loading control. Bar
graph represents the densitometric analysis of positive bands
normalized using the amount of fibrillarin; B: LNCaP cells
were treated, extracted and analyzed as described in A; C:
PC3 cells and D: LNCaP cells, treated as described in A, were
harvested and mRNA was extracted and analyzed by RT-PCR.
Data are expressed as mRNA level calculated by 2−ΔΔCt
method with respect to GAPDH mRNA. Results represent the
mean ± S.E.M. of data obtained by three independent ex-
periments. Statistical significance was: *p < 0.05.
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antibody anti-cyclin D1 (rabbit monoclonal clone SP4-R; Ventana
Medical Systems, Inc.) was incubated for 32min and 60min at 37 °C.
The slides were counterstained with hematoxylin, mounted and ana-
lyzed with Leica LAS V3.8 Software (Leica Microsystems, Switzerland)
associated with the Leica DMRB microscope.
2.8. Fluorescence in situ hybridization (FISH)
FISH analysis for CCND1 (Cyclin D1) gene copy number was per-
formed using SPEC CCND1/CEN 11 Dual Color Probe ZytoLight (Bio-
Optica, Germany), CCND1 gene was labeled with green fluorophore,
and CEN11 (centromere) was labeled with orange fluorophore, fol-
lowing the manufacturer's protocol.
For each specimen, at last 100 intact non-overlapping cells with
good signals were analyzed. FISH images were acquired at 63x mag-
nification utilizing Leica DM 6000B fluorescence microscope (Leica
Microsystems, Switzerland) equipped with DAPI, SpectrumGreen™,
SpectrumOrange™ filters. Images were processed by Leica LAS V3.8
Software (Leica Microsystems, Switzerland) to obtain a quantitative
analysis of genes.
2.9. Transmission electron microscopy (TEM)
After treatment, cells were immediately fixed in 2.5% cacodylate -
buffered glutaraldehyde, pH 7.3, for 2 h at 4 °C and pelleted by
centrifugation at 1200 rpm for 5′ at RT. Samples were washed overnight
in the same buffer, post-fixed in buffered 1% osmium tetroxide for 1 h,
dehydrated through a graded series of acetone and embedded in Epoxy
resin (Araldite, Fluka). Semithin sections (1 μm), were cut with a glass
knive on Leica EM UC7 Ultratome, stained with toluidine blue and
examined by light microscope for a general evaluation of cells mor-
phology. Ultrathin sections were cut with a diamond knife (Diatome) at
60–80 nm, retrieved onto copper grids, double-stained with Uranyl
Acetate Replacement Stain (UAR-EMS) and lead citrate and examined
at 100 kV with a Philips EM208 S electron microscope.
2.10. Flow cytometry
In order to analyze cell cultures by flow cytometry, the cells were
harvested from dishes by digesting with trypsin. Then the cells were
pelleted, at 800 g for 10min at 25 °C resuspended in PBS and fixed in
PBS plus 70% ethanol for 10min at 4 °C. After washing cells were in-
cubated with RNase A (50 μg/mL) for 30min at 37 °C, sequentially
stained with propidium iodide (100 μg/mL) for 1 h and analyzed by BD
Accuri C6 flow cytometer (BD Bioscience, Milano, Italy), to evaluate the
cell cycle progression.
The apoptosis/necrosis assay was performed using Annexin V-FITC
kits (Immunological Sciences), according to the manufacturer's in-
structions.
Fig. 3. Effects of NCPA on cell cycle progression. A: PC3 Cells, untreated (CTL), or treated with 0.5 mM NCPA for 24 h, 48 h and 72 h were analyzed by flow
cytometry, after treatment cells were harvested and stained with propidium iodide and analyzed with BD Accuri C6 flow cytometer. The percentage of cells in subG1,
G1, S and G2/M stages is indicated; B: LNCaP cells were treated and analyzed as in A. C: Statistical analysis conducted comparing the treated cells to untreated one
(* = p < 0.05).
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2.11. Statistics
All data were obtained from at least three independent experiments,
each performed either in duplicate or in triplicate. Data were statisti-
cally analyzed with two-way repeated measures analysis of variance
(ANOVA) with Bonferroni's multiple comparison test, using Prism 5.0
software (GraphPad Software, San Diego, CA, USA). P value < 0.05
was considered significant.
3. Results
3.1. Effect of NCPA on cell viability
To determine the dose-response and the time-course effect of NCPA
on cell viability, PC3 and LNCaP cells were exposed to 0.1, 0.5, and
1mM NCPA for 24 h, 48 h and 72 h. Cell viability was measured by MTS
method. NCPA significantly inhibited PC3 cell viability at 1mM con-
centration at all time points; it showed a slight detrimental effect at
0.5 mM at 24 h and 48 h, and a major detrimental effect at 72 h; finally,
it resulted ineffective at 0.1mM concentration at any time point
(Fig. 1A). NCPA did not affect LNCaP cell viability at any time point and
concentration used (Fig. 1A). PC3 cells treated with 0.5mM NCPA and
observed under optical microscope, showed a cell number decrease,
whereas treated LNCaP showed the same cell number of the untreated
ones (Fig. 1B). For further analyses, we decided to use 0.5 mM con-
centration, which is the concentration that induced 50% reduction in
cell viability in PC3 after 72 h treatment and it is also the same
concentration used in our previous publication on osteosarcoma cell
line [17].
3.2. Effect of NCPA on maspin production
To determine the effect of NCPA on Maspin production and Maspin
sub-cellular localization in PC3 and LNCaP, we analyzed those cell lines
treated with 0.5mM NCPA at different times by western blot. Nuclear
extract from NCPA-treated samples showed a statistically significant
increase of Maspin production after 24 h treatment (p < 0.05), which
returned back to control level after 48 h and 72 h treatment, in PC3 cell
line (Fig. 2A). NCPA did not stimulate Maspin production in LNCaP cell
line at any time point (Fig. 2B).
The increase in Maspin protein level in PC3 was concurrent with the
transcriptional up-regulation, which was statistically significant after
24 h treatment (*p < 0.05) and was not statistically significant after
48 h and 72 h (Fig. 2C). According to protein expression, in LNCaP
cells, NCPA was not able to affect Maspin mRNA expression level
(Fig. 2D).
3.3. Effect of NCPA on cell cycle progression and cell proliferation
The tumor suppressor molecule Maspin has been described to be
involved in several cell activities such as tumor cell motility, invasion,
metastasis and apoptosis. Considering that NCPA was able to stimulate
the Maspin production in PC3 and not in LNCaP cell line, we evaluated
the effect of this molecule on cell cycle progression in both cell lines by
Fig. 4. NCPA affects Cyclin D1 production
and CCND1 gene amplification. A: PC3 and
LNCaP cells untreated (CTL), or treated
with 0.5 mM NCPA for 48 h were analyzed
by immunocytochemistry using anti-Cyclin
D1 rabbit monoclonal antibody (original
magnification 20x, scale bar= 100 μm). B:
Bar graph representing the densitometric
analysis of positive nuclei in PC3 and
LNCaP cells, analyzed by ImageJ software;
C: PC3 and LNCaP cells, treated as de-
scribed in A, were analyzed by FISH using
SPEC CCND1/CEN 11 Dual Color Probe
ZytoLight, CCND1 labeled with green
fluorophore the cyclin D1 gene; CEN11 la-
beled the centromeres with orange fluor-
ophore (representative image, original
magnification 63x, scale bar= 10 μm). D:
Bar graph representing the CCND1 copy
number average in both cell lines; E:
Graphic representation of low-level CCND1
gene amplification (light grey) or non-am-
plified (dark grey) in PC3 and LNCaP cell
lines.
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flow cytometry.
The percentage of NCPA-treated PC3 cells in subG1 (G0/G1) stage
increased progressively at 24 h (15.1%), 48 h (16.7%) and remained
stable at 72 h (13.7%), whereas the percentage in G1 increased at all
analyzed times, at 24 h (59.8%), 48 h (65.3%, p < 0.05) and mainly at
72 h (69.8%, p < 0.05), alongside, percentage of cells in S (12.9% at
24 h, 7.4% at 48 h and 7.1% at 72 h, p < 0.05 for all time point ana-
lyzed) and G2/M (12.2% at 24 h, 10.6% at 48 h and 9.4% at 72 h,
p < 0.05 for 48h and 72h) stages decreased (Fig. 3A). The percentage
of LNCaP cells was almost the same in untreated and treated samples at
every time point, with no detectable subG1 (G0/G1) cells (Fig. 3B). The
statistical analysis was performed comparing treated cells to untreated
one (Fig. 3C).
3.4. Effect of NCPA on cyclin D1 (CCND1) gene amplification
Considering that Cyclin D1 protein is one of the major regulator of
the progression of cell cycle, we analyzed, by immunocytochemistry,
the presence of this protein in untreated and treated cells, finding that
Cyclin D1 was present in large amount in untreated PC3 cell nuclei, and
was significantly decreased in NCPA-treated PC3 cell nuclei (Fig. 4A
and B). According to the cell cycle analysis, LNCaP showed very low
amount of Cyclin D1 levels in untreated and treated cells, respectively
(Fig. 4A and B).
Cyclin D1 protein overexpression has been shown to be significantly
associated to high CCND1 gene amplification, for this reason we ana-
lyzed the CCND1 amplification by FISH [19]. Kim et al. defined “gene
amplification” as> 6 gene copies per nucleus in gastric cancer [20] and
Turner et al. found 4–10 CCND1 gene copies per nucleus in PC3 cell line
[21]. We analyzed CCND1 gene copy number in 100 nuclei both in
untreated and treated PC3 cells or LNCaP cells. A representative image
of all analyzed samples is reported (Fig. 4C). Comparing the average of
CCND1 gene amplification in both cell lines, we observed that CCND1
average is significantly decreased in PC3 treated cells, whereas CCND1
average was unchanged in LNCaP treated cells compared to untreated
ones (Fig. 4D). Amplification of CCND1 gene was detected in 40% of
PC3 untreated cells, while in NCPA-treated cells only in 4% of cells.
Conversely, in LNCaP untreated cells, amplification of CCND1 was
observed in 12% of cells, while in NCPA-treated cells was observed in
7% of cells (Fig. 4E).
Fig. 5. NCPA induces apoptosis in PC3 cell line. A: PC3 and LNCaP cells, untreated (CTL), or treated with 0.5 mM NCPA for 24 h, 48 h and 72 h were analyzed by flow
cytometry, after treatment, cells were harvested and the apoptosis/necrosis assay was performed using Annexin V-FITC kit for analysis with BD Accuri C6 flow
cytometer, the experiments were repeated at least three times. B: Statistical analysis conducted comparing early apoptosis, late apoptosis and necrosis stages in
treated cells with corresponding stages in untreated cells, (* = p < 0.05). C: Representative Transmission Electron Microscope images of untreated (CTL) and NCPA-
treated PC3 and LNCaP cells (0.5 mM for 72 h) (scale bar= 5 μm).
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3.5. Effect of NCPA on apoptosis in PC3
To verify the ability of NCPA to induce apoptosis, an apoptosis/
necrosis assay was performed by flow cytometry, revealing that NCPA
treatment induced apoptosis, both after 48 h and mainly after 72 h. The
percentage of early apoptosis was 1.2% and 1.3% after 48 h and 72 h
respectively, and late apoptosis 2.0% and 3.4% after 48 h and 72 h,
respectively, whereas, it was 0.1% early and 0.4% late apoptosis in
untreated cells. As observed in Fig. 5B, compared to the untreated cells,
a statistically significant increase in the ratio of apoptosis cells was
observed in 48h and 72h treated cells. LNCaP cells did not show any
apoptosis feature at any time point in accordance with cell cycle ana-
lysis (Fig. 5A).
To further demonstrate that cell death monitored by flow cytometry
was due to apoptosis we analyzed cells by TEM and we observed
apoptotic nuclei in NCPA-treated PC3 cells, whereas apoptotic nuclei
were not observed in LNCaP neither in untreated nor in treated cells
(Fig. 5B).
3.6. Effect of NCPA on LNCaP cells treated with AR inhibitor
In order to confirm that the stimulation of Maspin production in PC3
cell line was directly involved in the induction of apoptosis and con-
sequently in cell death, we analyzed if the stimulation of Maspin pro-
duction in LNCaP could induce the same effects. LNCaP are hormone-
sensible cells and in the promoter region of Maspin, a Hormone
Responsive Element that negatively controls the Maspin production is
present [10]. We treated the LNCaP cells with Bicalutamide, an An-
drogen Receptor (AR) inhibitor and then with NCPA, finding that it
induced a statistically significant cell death compared to untreated
cells, but the co-treatment with NCPA further induced cell death sig-
nificantly higher than Bicalutamide alone, with the highest effect after
72 h (Fig. 6A). In order to verify if the treatment with Bicalutamide
could induce the production of Maspin, we performed a western blot
experiment, analyzing the nuclear extract, and found that the treatment
with Bicalutamide alone stimulated Maspin production, but the treat-
ment with Bicalutamide plus NCPA induced a very large amount and
nuclear accumulation of Maspin (Fig. 6B). Finally, we analyzed cell
cycle progression and apoptosis/necrosis induction finding that the pre-
treatment with Bicalutamide and treatment with NCPA induced the
Fig. 6. Effects of NCPA on LNCaP pre-treated with hormone receptor inhibitor Bicalutamide. A: Cell viability was assessed by MTS (3-[4,5-dimethylthiazol-2-yl]-5-
[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium) based colorimetric assay. Cells were left untreated (CTL) or treated with Bicalutamide for 72 h or pre-
treated ON with Bicalutamide and treated with 0.5 mM NCPA, for 24 h, 48 h and 72 h. Statistical significance: *p < 0.05, **p < 0.01; B: Proteins from LNCaP cells
treated as in A, were extracted and nuclear extract was analyzed by Western blot, using anti-Maspin antibody and anti-Fibrillarin as loading control. Bar graph
represents the densitometric analysis of positive bands normalized using the amount of fibrillarin. Statistical significance: *p < 0.05, **p < 0.01; C: LNCaP cells
treated as in A, were stained with propidium iodide and cycle progression was analyzed with BD Accuri C6 flow cytometer. The experiments were repeated three
times. The percentage of cells in subG1, G1, S and G2/M stages is indicated; D: LNCaP cells treated as in A, were harvested and the apoptosis/necrosis assay was
performed using Annexin V-FITC kit for analysis with BD Accuri C6 flow cytometer. The experiments were repeated three times, a statistical analysis has been
conducted comparing the sample treated with Bicalutamide alone with sample treated with Bicalutamide plus NCPA, the statistical significance has been reported in
Results section.
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increase of cell number in subG1 stage 65.4% Bicalutamide alone at
72 h, 61% at 24 h, 79.8% at 48 h and 79.5% at 72h after NCPA treat-
ment (Fig. 6C). The increase of cell number in subG1 in Bicalutamide
plus NCPA at 72h was statistically significant compared to the apoptosis
rate in Bicalutamide alone at 72h (p < 0.05). The apoptosis/necrosis
assay showed that Bicalutamide treatment induced early apoptosis,
7.8% at 72 h, whereas Bicalutamide plus NCPA induced an increased
percentage of cells in early apoptosis, 4.1%, 15.5% and 20.2% at 24 h,
48 h and 72 h, respectively (Bicalutamide plus NCPA vs Bicalutamide
alone at 72h was statistically significant, p < 0.01). Same result was
obtained for late apoptosis, Bicalutamide alone 4.6% at 72 h, Bicalu-
tamide plus NCPA 5.1%, 28.6% and 51.3% at 24 h, 48 h and 72 h, re-
spectively (Bicalutamide plus NCPA vs Bicalutamide alone at 72h was
statistically significant, p < 0.001) (Fig. 6D).
4. Discussion
Maspin, a non-inhibitory member of the serine protease inhibitor
superfamily, Serpin B, has been characterized as a class II tumor sup-
pressor gene in several cancer types, such as breast, lung, epithelial and
prostate cancer [6,8,22,23], due to its ability to inhibit cell invasiveness
and angiogenesis, and to increase apoptosis [4], therefore inhibiting
metastasis [24]. These Maspin features are of utmost interest in medical
field suggesting that Maspin complies a role as a therapeutic agent for
several forms of malignancies [4,25]. In normal prostate epithelial cells,
Maspin is highly expressed and is found localized in cytoplasm, nucleus,
secretory vesicles and occasionally at cell surface [25,26], whereas in
prostate cancer cell lines, PC3, LNCaP and DU145, its expression is
almost completely suppressed [27]. Moreover, Maspin has been found
highly expressed in tumor specimens from patients treated with
neoadjuvant androgen ablation therapy [11]. On the other hand, pa-
tients with Maspin expressing prostate cancer had a significantly longer
survival rate [25,28].
Previously, in our laboratory, we studied glucosamine (GlcN) and a
glucosamine-derivative, NAPA, which showed a good anti-in-
flammatory activity inhibiting p38 and JNK kinases, and in turn in-
terfere with AP-1 pathway [29,30]. GlcN and mainly NAPA were also
able to inhibit NF-κB pathway, particularly by inhibiting IKKα migra-
tion into the nucleus and its kinase activity [16]. IKKα belongs to IKK
complex, which controls the activation of NF-κB pathway, and con-
sidering that recently, the nuclear role of IKKα has been associated to
cancer progression through repression of Maspin expression [14], we
decided to study whether our molecules could be able to interfere with
Maspin production. In order to obtain a more effective IKKα inhibitor,
we synthesized a new glucosamine-derivative, 2-(N-Carbobenzyloxy)L-
phenylalanylamido-2-deoxy-β-D-glucose (NCPA), which revealed to be
very effective in inhibiting IKKα and to stimulate Maspin production in
osteosarcoma cell lines, 143B and Saos-2 [17]. We decided to analyze
the effectiveness of NCPA in two human prostate cancer cell lines, PC3
and LNCaP, which have been extensively used as models to study the
progression of this type of tumor. LNCaP cell line is considered an early
stage of prostate cancer, whose development is based on androgen-
sensitive cell growth [31,32], and the progression has been shown to be
based on an androgen receptor (AR)-independent cell growth [33]. On
the other hand, PC3 cell line is considered representative of advanced
disease, due to its source of origin and to androgen-insensitive features
[34,35]. The AR is not expressed in PC3, and this cell line is more ag-
gressive compared to LNCaP. Moreover, the androgen-insensitivity, due
to lack of AR expression, is associated to more aggressive tumor phe-
notype in some patients. Considering the differences between LNCaP
and PC3 we decided to analyze the effects of NCPA on both cell lines,
focusing the attention on the ability to stimulate Maspin production.
The first difference we found was that NCPA was able to inhibit cell
viability in PC3 and not in LNCaP. Moreover, our molecule stimulated
the production of Maspin only in PC3, which was mainly localized in
the nuclear fraction. This finding is noteworthy, considering that
several authors described this localization as essential for its tumor
suppressor activity [7,8,36,37]. Goulet et al. demonstrated that nuclear
Maspin is physically associated to target gene promoters, suggesting
that its metastasis suppressor functions could involve, at least in part,
this kind of mechanism [36].
The tumor-suppressing and anti-metastatic activities of Maspin have
been also attributed to its ability to inhibit cell cycle progression and to
stimulate apoptosis of tumor cells [25,26,38]. Therefore, we analyzed
the effects of NCPA on PC3 and LNCaP cell lines, with regard to those
processes, finding that the compound caused a cell cycle progression
blockage in PC3, whereas cell cycle progression of treated LNCaP cells
was not affected. Cyclin D1 is considered a key regulator of the pro-
gression of cell cycle through G1 phase and its overexpression is also
been related to the evolution of androgen-independent prostate cancer
[39]. Analyzing the expression level of Cyclin D1 both in PC3 and
LNCaP, we found that Cyclin D1 was up-regulated in PC3 and not in
LNCaP and that the NCPA treatment decreased the expression level in
PC3. Our data are in agreement with those of Lee et al., who found that
the arrest in G1 phase was related to decrease of Cyclin D1 and up-
regulation of Maspin in Oral Squamous Cell Carcinoma Cells [40]. The
overexpression of Cyclin D1 has been associated to gene amplification
mainly in hormone-insensitive and metastatic prostate cancer samples,
whereas, the amplification rate is very low in early stage prostate
cancer samples [19]. According to these findings, we found that CCND1
gene is largely amplified in PC3 cell line, representing an advanced and
hormone-insensitive prostate cancer, and is barely amplified in LNCaP,
representing an early stage and hormone-sensitive prostate cancer. In-
terestingly, NCPA was effective mainly in PC3 cells decreasing the cell
number with amplified CCND1 from 40% to 4%. In LNCaP, the per-
centage of cells with CCND1 gene amplification was only 12% and was
lowered to 7% after treatment, which was not statistically significant.
Turner et al. found that the amplification of some common oncogenes,
among them CCND1, can be attributed to extra chromosomal DNA
(ecDNA) [21]. Anyway, they found that CCDN1 amplification in PC3
cell line is not due to ecDNA, but resides on chromosomal loci [21]. We
can speculate that NCPA could be effective mainly in cell with CCND1
chromosomal loci amplification. The data on CCND1 amplification are
in agreement with analysis of tubulin filaments, performed by im-
munofluorescence, showing a large amount of mitotic spindles in un-
treated PC3 compared to NCPA-treated PC3. Moreover, the number of
mitotic spindles was lower in untreated LNCaP compared to untreated
PC3 (Supplementary Fig. 1).
Finally, we analyzed the ability of NCPA to induce apoptosis in PC3
cells, finding that progressively the percentage of both early and late
apoptotic cells was increased, with the higher amount at 72 h. This is in
agreement with the increase of nuclear Maspin at 24 h, suggesting that
the nuclear activity of this protein gives rise to the production of mo-
lecules involved in apoptosis processes. Noteworthy, the amount of
Maspin was slightly increased again at 72 h suggesting that this in-
hibitor could support the apoptotic process.
Interestingly, Coulson-Thomas et al. demonstrated that, in the early
phases of prostate cancer development, the tumor cells are surrounded
by Lumican, a Small Leucine-rich proteoglycan (SLRP), which inhibits
tumor progression and invasion [41]. During cancer progression, the
cancer cells increase the production of MMPs degrading the deposited
stromal lumican. Moreover, Villermoz et al. showed that the over-
expression of lumican in a mouse cancer model induced the decrease of
Cyclin D1 production, increased apoptosis rate and in turn significantly
decreased subcutaneous tumor formation in vivo [42]. Previously, we
demonstrated that GlcN and glucosamine-derivative NAPA, were able
to stimulate extracellular matrix components, among them also the
SLRP lumican and collagens [43,44]. Considering that NCPA is a glu-
cosamine-derivative, very similar to NAPA, we can hypothesize that
also NCPA induces lumican production, strengthening the effects on cell
cycle and apoptosis that we observed. Moreover, Dzinic et al. showed
that Maspin is involved in the production of extracellular matrix in
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prostate cancer cell line [45].
A hormone negative regulatory element is present in the promoter
region of Maspin gene [10].
Taking into account this finding, Zou et al. [11] demonstrated that
LNCaP cultured in androgen-depleted medium exhibit induction of
Maspin expression. We treated LNCaP with AR inhibitor Bicalutamide
and with Bicalutamide plus NCPA finding that our molecule, in this
condition, was able to induce the expression of Maspin also in LNCaP
cells and in turn was able to promote the apoptosis. In particular, Bi-
calutamide plus NCPA induced a higher production of Maspin com-
pared to Bicalutamide alone, and consequently also the apoptosis rate
was higher in Bicalutamide plus NCPA compared to Bicalutamide alone.
Considering that Bicalutamide barely induced apoptosis and NCPA was
not effective at all on LNCaP cells, whereas the contemporary admin-
istration of Bicalutamide plus NCPA induced 51,3% late apoptosis rate,
we suggest that the combination of two molecules results in a sy-
nergistic effect on cell line. This evidence highlights the possibility of a
use of NCPA as a chemosensitizing agent.
In conclusion, we demonstrated that our molecule glucosamine-
derivative, NCPA, stimulated Maspin production both in PC3 and in
LNCaP cell line pre-treated with a hormone inhibitor, inducing the
apoptosis. The increase of autologous Maspin, would be a desirable
therapeutic strategy, considering that the delivery of recombinant
Maspin by adenoviral construct or liposomal DNA complexes is ac-
companied with safety and efficacy issues [22,46].
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